OBJECTIVE: The objective of this study were to (1) quantify the concentrations of inhibin A, activin A, and follistatin in maternal serum and umbilical vein (inhibin A, activin A) in IUGR due to placental dysfunction pregnancies and control group, (2) determine the concentration differences of these factors in maternal and umbilical vein serum in control and subject group, and (3) examine the relationship between fetal growth and placental function. METHOD: Sandwich ELISA was used to measure the concentrations in control (n = 40) and subject groups (n = 30). RESULTS: Umbilical vein serum inhibin A, activin A concentrations were increased in subject group compared with controls (inhibin A regression coefficient, 0.7647, P < 0.001, activin A P < 0.0005). Maternal serum inhibin A, activin A were significantly increased in subject group compared with controls (inhibin A regression coefficient, 0.7614, P < 0.001, activin A P < 0.0005). Maternal serum activin: follistatin ratio was significantly increased in subject group compared with controls (P < 0.0005). Maternal serum inhibin A, activin A concentrations were more when compared to the umbilical vein inhibin A, activin A concentrations in subject group. CONCLUSION: The present study strengthens the evidence of using inhibin A, activin A, and follistatin as serum markers in routine screening for early detection of IUGR. But large prospective studies are needed to further define their role in clinical practice.
OBJECTIVE: The objective of this study were to (1) quantify the concentrations of inhibin A, activin A, and follistatin in maternal serum and umbilical vein (inhibin A, activin A) in IUGR due to placental dysfunction pregnancies and control group, (2) determine the concentration differences of these factors in maternal and umbilical vein serum in control and subject group, and (3) examine the relationship between fetal growth and placental function. METHOD: Sandwich ELISA was used to measure the concentrations in control (n = 40) and subject groups (n = 30). RESULTS: Umbilical vein serum inhibin A, activin A concentrations were increased in subject group compared with controls (inhibin A regression coefficient, 0.7647, P < 0.001, activin A P < 0.0005). Maternal serum inhibin A, activin A were significantly increased in subject group compared with controls (inhibin A regression coefficient, 0.7614, P < 0.001, activin A P < 0.0005). Maternal serum activin: follistatin ratio was significantly increased in subject group compared with controls (P < 0.0005). Maternal serum inhibin A, activin A concentrations were more when compared to the umbilical vein inhibin A, activin A concentrations in subject group. CONCLUSION: The present study strengthens the evidence of using inhibin A, activin A, and follistatin as serum markers in routine screening for early detection of IUGR. But large prospective studies are needed to further define their role in clinical practice.
Authors: May Lee Tjoa; Cees B M Oudejans; John M G van Vugt; Marinus A Blankenstein; Inge J van Wijk Journal: Hypertens Pregnancy Date: 2004 Impact factor: 2.108
Authors: P Florio; L Cobellis; S Luisi; P Ciarmela; F M Severi; C Bocchi; F Petraglia Journal: Mol Cell Endocrinol Date: 2001-06-30 Impact factor: 4.102
Authors: D D'Antona; F M Reis; C Benedetto; L W Evans; N P Groome; D M de Kretser; E M Wallace; F Petraglia Journal: J Endocrinol Date: 2000-04 Impact factor: 4.286
Authors: Dustin T Yates; Derek S Clarke; Antoni R Macko; Miranda J Anderson; Leslie A Shelton; Marie Nearing; Ronald E Allen; Robert P Rhoads; Sean W Limesand Journal: J Physiol Date: 2014-05-23 Impact factor: 5.182